Approx. Rs 9,600 / PieceGet Latest PriceProduct BrochureProduct Details:
|Minimum Order Quantity||1 Piece|
|Usage/Application||treat growth failure in children and adults who lack natural growth hormone|
|Composition||Human Growth Hormone Injection|
|Packaging Size||injection 36iu,packaging size:1 prefilled penper box,(12 mg/ml)|
|Dose||Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended. Prader-Willi Syndrome. Gene|
Approx. Rs 750 / VialGet Latest PriceProduct BrochureProduct Details:
|Minimum Order Quantity||10 Vial|
|Composition||Human Growth Horman inj|
|Packaging Size||4 iu x 10 vial|
|Injectable Form||Lyophilized Powder|
|Usage||To treat Growth Hormone Deficiency (GHD)|
|Shelf Life||2 Year|
|Country of Origin||Made in India|
Approx. Rs 14,826.56 / PieceGet Latest PriceProduct BrochureProduct Details:
|Brand Name||Genryzon 60 24 mg 1.2mL Somatrogon|
|Prescription/ Non Prescription||Prescription|
Genryzon (Somatrogon), is a medication for the treatment of growth hormone deficiency. Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal.
Genryzon (somatrogon) is a synthetic growth hormone that works by replacing the lack of growth hormone in the body. Genryzon is taken by injection just below the skin. Compared to the growth hormone GENOTROPIN® (somatropin), its action in the body lasts longer, enabling weekly injections instead of daily. Genryzon is approved for the treatment of pediatric growth hormone deficiency (GHD) in Canada, Australia and Japan, and the EU marketing authorization is valid in all EU Member States as well as Iceland, Norway and Liechtenstein.
The next-generation long-acting recombinant human growth hormone somatrogon, is a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. Genryzon provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once weekly.
GHD is a rare disease characterized by the inadequate secretion of the growth hormone, somatropin, from the pituitary gland and affects one in approximately 4,000 to 10,000 children worldwide. The disease can be caused by genetic mutations or acquired after birth. Without treatment, affected children will have persistent growth attenuation and a very short height in adulthood, and puberty may be delayed.Children may also experience other problems with physical health and mental well-being.
The safety and efficacy of Genryzon (somatrogon) was demonstrated in a randomized, open-label, active-controlled Phase 3 study conducted in over 20 countries. In this study, 224 prepubertal, treatment-naïve children with growth hormone deficiency (GHD) were randomized 1:1 to receive NGENLA once-weekly or GENOTROPIN® (somatropin) once-daily. The study met its primary endpoint of Genryzon non-inferiority compared to GENOTROPIN, as measured by annual height velocity at 12 months. Genryzon was generally well tolerated in the study and had a safety profile comparable to GENOTROPIN. Participants had the opportunity to enroll in a global, open-label, multicenter, long-term extension study in which they were able to either continue receiving or switch to Genryzon. Approximately 95% of the patients switched into the open-label extension study and received Genryzon treatment.
Explore More Products